Bay Harbor Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bay Harbor Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.4K	Buy	27 +9	+50%	+$3.99K	﹤0.01%	233
2026 Q1	$8.04K	Buy	18 +3	+20%	+$1.4K	﹤0.01%	263
2025 Q4	$6.8K	Buy	15 +6	+67%	+$2.59K	﹤0.01%	226
2025 Q3	$3.52K	Buy	9 +2	+29%	+$836	﹤0.01%	262
2025 Q2	$3.12K	Buy	7 +2	+40%	+$922	﹤0.01%	228
2025 Q1	$2.42K	Buy	+5	New	+$2.33K	﹤0.01%	180
2020 Q3	–	Sell	-7	Closed	-$2K	–	416
2020 Q2	$2K	Buy	+7	New	+$1.9K	﹤0.01%	297

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bay Harbor Wealth Management's VRTX Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, buying an estimated $3.99K and bringing the position to 27 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #233.

Bay Harbor Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 7 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Bay Harbor Wealth Management held 27 shares of Vertex Pharmaceuticals worth $13.4K as of Q2 2026.
Bay Harbor Wealth Management bought 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
Vertex Pharmaceuticals made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #233 holding.
Bay Harbor Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.